madman
Super Moderator
Truly impressive!
* the really exciting data of SYNCHRONIZE-1 was not the weight loss it was actually the metabolic health gains so we see that there was an improvement in glycemia and blood pressure but there was a. 63% REDUCTION IN FAT IN THE LIVER so imagine you had 16% weight loss but 25% REDUCTION IN SUBCUTANEOUS FAT, 34% REDUCTION IN VISCERAL FAT and 63% REDUCTION IN LIVER FAT so ultimately patients are losing much more fat than they lose lean mass
New findings from the SYNCHRONIZE-1 trial reveal that survodutide's impact extends beyond weight reduction, with a demonstrated decrease in liver fat and meaningful improvements across multiple markers of metabolic health in patients without type 2 diabetes. Dr. Carel le Roux joins us to share the efficacy and safety data and explore what these results could mean for the future of metabolic disease management. Dr. Le Roux is the Director of the Metabolic Medicine Group and a Professor of Chemical Pathology in the School of Medicine at University College Dublin, and he presented these findings at the 2026 American Diabetes Association Scientific Sessions.
* the really exciting data of SYNCHRONIZE-1 was not the weight loss it was actually the metabolic health gains so we see that there was an improvement in glycemia and blood pressure but there was a. 63% REDUCTION IN FAT IN THE LIVER so imagine you had 16% weight loss but 25% REDUCTION IN SUBCUTANEOUS FAT, 34% REDUCTION IN VISCERAL FAT and 63% REDUCTION IN LIVER FAT so ultimately patients are losing much more fat than they lose lean mass
New findings from the SYNCHRONIZE-1 trial reveal that survodutide's impact extends beyond weight reduction, with a demonstrated decrease in liver fat and meaningful improvements across multiple markers of metabolic health in patients without type 2 diabetes. Dr. Carel le Roux joins us to share the efficacy and safety data and explore what these results could mean for the future of metabolic disease management. Dr. Le Roux is the Director of the Metabolic Medicine Group and a Professor of Chemical Pathology in the School of Medicine at University College Dublin, and he presented these findings at the 2026 American Diabetes Association Scientific Sessions.
